BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL)

Authors
Category Primary study
JournalBlood
Year 2014
This article has no abstract
Epistemonikos ID: 15239a9d153f0fae34c8a135db1560adcc5c016b
First added on: Feb 19, 2025